Physician profile
Aslam Khan
NPI 1053572123
$2,514.18
in general payments reported to CMS, 2019-2025
14 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.67 · 2021: $243 · 2022: $611 · 2023: $231 · 2024: $1,250 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883 · Travel and Lodging: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.10 |
| Travel and Lodging | $756.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,168.71 | 2021-2024 | |
| Boston Scientific Corporation | $576.34 | 2022-2023 | Latitude Communicator Power Supply |
| Medtronic, INC. | $207.30 | 2021 | |
| Pfizer INC. | $162.18 | 2022-2025 | |
| Biosense Webster, INC. | $126.48 | 2023 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $65.74 | 2023-2024 | Camzyos |
| Novo Nordisk INC | $45.20 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $36.38 | 2020-2022 | |
| Scpharmaceuticals INC. | $30.66 | 2025 | |
| Amgen INC. | $30.56 | 2025 | Repatha, Repatha |
| Abbott Laboratories | $24.79 | 2024 | Cardiomems |
| Convatec INC. | $22.42 | 2024 | |
| Lilly USA, LLC | $17.42 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aslam Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.